Literature DB >> 25333008

ERCC1 and personalized medicine in lung cancer.

Jeong Seon Ryu1, Azra Memon1, Seul-Ki Lee1.   

Abstract

Excision repair cross-complementing group 1 (ERCC1) is known to be a key player in nucleotide excision repair (NER) pathway. Its prognostic or predictive relevance has been extensively investigated in cancer patients including non-small-cell lung cancer. However, several questions should be addressed before its clinical application as biomarker for patient classification or guiding platinum treatment.

Entities:  

Keywords:  Biomarker; excision repair cross-complementing group 1 (ERCC1); non-small-cell lung cancer; personalized medicine

Year:  2014        PMID： 25333008      PMCID： PMC4200610          DOI： 10.3978/j.issn.2305-5839.2013.12.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  10 in total

1.  Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients.

Authors:  C M Choi; S C Yang; H J Jo; S Y Song; Y J Jeon; T W Jang; D J Kim; S H Jang; S H Yang; Y D Kim; K H Lee; S J Jang; Y T Kim; D K Kim; D H Chung; L Kim; H S Nam; J H Cho; H J Kim; J S Ryu
Journal:  Ann Oncol       Date:  2012-02-08       Impact factor: 32.976

2.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

4.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

5.  Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

Authors:  Jeong-Seon Ryu; Yun-Chul Hong; Hye-Seung Han; Jong-Eun Lee; Sook Kim; Young-Mee Park; Young-Chul Kim; Tae-Sook Hwang
Journal:  Lung Cancer       Date:  2004-06       Impact factor: 5.705

6.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

7.  Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Authors:  Reginald V N Lord; Jan Brabender; David Gandara; Vicente Alberola; Carlos Camps; Manuel Domine; Felip Cardenal; José M Sánchez; Paul H Gumerlock; Miquel Tarón; José J Sánchez; Kathleen D Danenberg; Peter V Danenberg; Rafael Rosell
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

8.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Authors:  Gerold Bepler; Charles Williams; Michael J Schell; Wei Chen; Zhong Zheng; George Simon; Shirish Gadgeel; Xiuhua Zhao; Fred Schreiber; Julie Brahmer; Alberto Chiappori; Tawee Tanvetyanon; Mary Pinder-Schenck; Jhanelle Gray; Eric Haura; Scott Antonia; Juergen R Fischer
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

9.  ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Authors:  Luc Friboulet; Ken André Olaussen; Jean-Pierre Pignon; Frances A Shepherd; Ming-Sound Tsao; Stephen Graziano; Robert Kratzke; Jean-Yves Douillard; Lesley Seymour; Robert Pirker; Martin Filipits; Fabrice André; Eric Solary; Florence Ponsonnailles; Angélique Robin; Annabelle Stoclin; Nicolas Dorvault; Frédéric Commo; Julien Adam; Elsa Vanhecke; Patrick Saulnier; Jürgen Thomale; Thierry Le Chevalier; Ariane Dunant; Vanessa Rousseau; Gwénaël Le Teuff; Elisabeth Brambilla; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

Review 10.  The DNA damage response: making it safe to play with knives.

Authors:  Alberto Ciccia; Stephen J Elledge
Journal:  Mol Cell       Date:  2010-10-22       Impact factor: 17.970
  10 in total
  9 in total

1.  Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer.

Authors:  Wentao Li; Jichen Qu; Zhifei Xu
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

2.  Improving accuracy of diagnostic studies in a world with limited resources: a road ahead.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Ann Transl Med       Date:  2016-02

3.  Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma.

Authors:  Jinfeng Gan; Yuling Zhang; Xiurong Ke; Chong Tan; Hongzheng Ren; Hongmei Dong; Jiali Jiang; Shaobin Chen; Yixuan Zhuang; Hao Zhang
Journal:  Int J Mol Sci       Date:  2015-05-27       Impact factor: 5.923

4.  The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.

Authors:  Marina Piljić Burazer; Suzana Mladinov; Vesna Ćapkun; Sendi Kuret; Merica Glavina Durdov
Journal:  Med Sci Monit       Date:  2017-01-27

5.  Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study.

Authors:  Spoorti Kulkarni; Monica Solomon; Deepthi Pankaj; Sunitha Carnelio; Chetana Chandrashekar; Nisha Shetty
Journal:  J Oral Maxillofac Pathol       Date:  2020-05-08

6.  Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.

Authors:  Chi Pan; Huijie Duan; Yinan Wu; Chunpeng Zhu; Chenghao Yi; Yin Duan; Demin Lu; Cheng Guo; Deqi Wu; Yanyan Wang; Xianhua Fu; Jing Xu; Yiding Chen; Meng Luo; Wei Tian; Tao Pan; Wenhong Xu; Suzhan Zhang; Jianjin Huang
Journal:  Int J Oncol       Date:  2020-07-27       Impact factor: 5.650

7.  Quantile Graphical Models: Bayesian Approaches.

Authors:  Nilabja Guha; Veera Baladandayuthapani; Bani K Mallick
Journal:  J Mach Learn Res       Date:  2020       Impact factor: 5.177

8.  Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.

Authors:  Olga Papadodima; Panagiotis Moulos; Aggeliki Koryllou; Georgia Piroti; Fragiskos Kolisis; Aristotelis Chatziioannou; Vasiliki Pletsa
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

9.  Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.

Authors:  Marina Piljić Burazer; Suzana Mladinov; Antonela Matana; Sendi Kuret; Joško Bezić; Merica Glavina Durdov
Journal:  Diagn Pathol       Date:  2019-09-14       Impact factor: 2.644
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.